Latrophilin receptors: novel bronchodilator targets in asthma

Latrophilin receptors: novel bronchodilator targets in asthma

BACKGROUND Asthma affects 300 million people worldwide. In asthma, the major cause of morbidity and mortality is acute airway narrowing, due to airway smooth muscle (ASM) hypercontraction, associated with airway remodelling. However, little is known about the transcriptional differences between healthy and asthmatic ASM cells. OBJECTIVES To investigate the transcriptional differences between ...

Bronchodilator, Terbutaline, in Asthma

subnormal responses found in patients given interriittent COT ticosteroid therapy by Malone et al. (1970). This finding, together with the satisfactory clinical response in these patients with severe disease, suggests that a therapeutic trial of depot tetracosactrin in a dose of 0-5 mg twice weekly should be considered for the control of disease requiring steroid therapy over a prolonged period...

P 107: P2x7 Receptors: as a Novel Targets for the Treatment of Neuroinflammation

P2x7 receptors are Purineric receptors that are extracellular ATP-gated ion channel. These receptors require high dose or prolonged exposure to ATP for initial activation. The Activation of these receptors facilitates the formation of inflammasome which activates caspase 1. The P20 and P10 subunits of caspase 1 form active enzyme that then releases active interleukin (IL)-1 β and IL-18, tu...

Chemokine receptors in asthma: searching for the correct immune targets.

Breathing therapies and bronchodilator use in asthma.

T reatments involving the manipulation of breathing are commonly used in routine practice by physiotherapists and other practitioners in a variety of clinical settings yet, despite decades of use, there is no robust evidence base to confirm the effectiveness of these activities. Practical and logistic difficulties exist in the design and execution of the randomised controlled clinical trials re...